Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Anesthesiology ; 118(2): 344-9, 2013 02.
Article in English | MEDLINE | ID: mdl-23460944

ABSTRACT

BACKGROUND: Malignant hyperthermia (MH, MIM# 145600) is a complex pharmacogenetic disorder that is manifested in predisposed individuals as a potentially lethal reaction to volatile anesthetics and depolarizing muscle relaxants. Studies of CASQ1-null mice have shown that CASQ1, encoding calsequestrin 1, the major Ca2+ binding protein in the lumen of the sarcoplasmic reticulum, is a candidate gene for MH in mice. The aim of this study was to establish whether the CASQ1 gene is associated with MH in the North American population. METHODS: The entire coding region of CASQ1 in 75 unrelated patients diagnosed by caffeine-halothane contracture test as MH susceptible (MHS) was analyzed by DNA sequencing. Subsequently, three groups of unrelated individuals (130 MHS, 100 MH negative, and 192 normal controls) were genotyped for a variant that was identified by sequencing. Levels of CASQ1 expression in the muscle from unrelated MHS and MH negative individuals were estimated by Western blotting. RESULTS: Screening of the entire coding sequence of the CASQ1 gene in 75 MHS patients revealed a single variant c.260T > C (p.Met87Thr) in exon 1. This variant is unlikely to be pathogenic, because its allele frequency in the MHS group was not significantly different from that of controls. There was also no difference in calsequestrin 1 protein levels between muscle samples from MHS and controls, including those carrying the p.Met87Thr variant. CONCLUSIONS: This study revealed a low level of protein coding sequence variability within the human CASQ1 gene, indicating that CASQ1 is not a major MHS locus in the North American population.


Subject(s)
Calcium-Binding Proteins/genetics , Malignant Hyperthermia/epidemiology , Malignant Hyperthermia/genetics , Mitochondrial Proteins/genetics , Amino Acid Sequence , Blotting, Western , Calcium Channels/genetics , Calcium Channels, L-Type , Calsequestrin , Computational Biology , DNA/genetics , Exons/genetics , Humans , Introns/genetics , Molecular Sequence Data , Muscle, Skeletal/metabolism , North America/epidemiology , RNA/genetics , Retrospective Studies , Ryanodine Receptor Calcium Release Channel/genetics , White People
2.
Neuromuscul Disord ; 23(2): 120-32, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23183335

ABSTRACT

Central core disease, one of the most common congenital myopathies in humans, has been linked to mutations in the RYR1 gene encoding the Ca(2+) release channel of the sarcoplasmic reticulum (RyR1). Functional analyses showed that disease-associated RYR1 mutations led to impairment of skeletal muscle Ca(2+) homeostasis; however, thorough understanding of the molecular mechanisms underlying central core disease and other RyR1-related conditions is still lacking. We screened by sequencing the complete RYR1 transcripts in ten unrelated patients with central core disease and identified five novel, p.M4640R, p.L4647P, p.F4808L, p.D4918N and p.F4941C, and four recurrent mutations. Four of the novel mutations involved amino acid residues that were positioned within putative transmembrane segments of the RyR1. The pathogenic character of the identified mutations was demonstrated by bioinformatic analyses and by the in vitro functional studies in HEK293 cells and RYR1-null (dyspedic) myotubes. Characterization of Ca(2+) channel properties of RyR1s carrying one recurrent and two novel mutations upholds the view that diminished intracellular Ca(2+) release caused by impaired Ca(2+) channel gating and/or Ca(2+) permeability is an important component of central core disease etiology. This study expands the list of functionally characterized disease-associated RyR1 mutations, increasing the value of genetic diagnosis for RyR1-related disorders.


Subject(s)
Muscle Contraction/physiology , Mutation/genetics , Myopathy, Central Core/genetics , Myopathy, Central Core/physiopathology , Ryanodine Receptor Calcium Release Channel/genetics , Adolescent , Adult , Calcium/metabolism , Cells, Cultured , Child , Child, Preschool , Female , Genetic Testing , HEK293 Cells , Homeostasis/physiology , Humans , Infant , Infant, Newborn , Male , Muscle Fibers, Skeletal/metabolism , Myopathy, Central Core/diagnosis , Pedigree , Polymorphism, Genetic/genetics , Retrospective Studies , Ryanodine Receptor Calcium Release Channel/metabolism
3.
Can J Anaesth ; 58(6): 504-13, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21455645

ABSTRACT

PURPOSE: Malignant hyperthermia (MH) is an autosomal dominant pharmacogenetic disorder that is manifested on exposure of susceptible individuals to halogenated anesthetics or succinylcholine. Since MH is associated primarily with mutations in the ryanodine receptor type 1 (RYR1) gene, the purpose of this study was to determine the distribution and frequency of MH causative RyR1 mutations in the Canadian MH susceptible (MHS) population. METHODS: In this study, we screened a representative cohort of 36 unrelated Canadian MHS individuals for RYR1 mutations by sequencing complete RYR1 transcripts and selected regions of CACNA1S transcripts. We then analyzed the correlation between caffeine-halothane contracture test (CHCT) results and RYR1 genotypes within MH families. RESULTS: Eighty-six percent of patients had at least one RyR1 mutation (31 out of 36), five of which were unrelated individuals who were double-variant carriers. Fifteen of the 27 mutations identified in RYR1 were novel. Eight novel mutations, involving highly conserved amino acid residues, were predicted to be causal. Two of the mutations co-segregated with the MHS phenotype within two large independent families (a total of 79 individuals). Fourteen percent of MHS individuals (five out of 36) carried neither RYR1 nor known CACNA1S mutations. CONCLUSIONS: The distribution and frequency of MH causative RyR1 mutations in the Canadian MHS population are close to those of European MHS populations. Novel mutations described in this study will contribute to the worldwide pool of MH-associated mutations in the RYR1 gene, ultimately increasing the value of MH genetic diagnostic testing.


Subject(s)
Malignant Hyperthermia/genetics , Mutation , Ryanodine Receptor Calcium Release Channel/genetics , Amino Acid Sequence , Genetic Association Studies , Humans , Molecular Sequence Data , Polymorphism, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL
...